However, it is during the recovery period when the sulfonylureas differed significantly
Nov 12, 2019 · At least one sulfonylurea—glimepiride—is not guilty of increasing short-term cardiovascular risk
Glyburide has been
However, nonspecific, long-acting sulfonylureas glyburide and glimepiride have an increased risk of severe hypoglycemia
However, it is
Hypoglycemia limits the glycemic control that can be achieved with insulin and sulfonylureas (SUs) , but we lack evidence from head-to-head studies to guide
The CAROLINA trial (Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes) compared the effects of glimepiride, a
Ottawa (ON): Canadian Agency for Drugs and